Pyxis Oncology financials
$2.900.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $13.9M | $16.1M | $0.00 | $0.00 | — |
| Gross profit | $11.5M | $15.7M | $0.00 | $0.00 | — |
| Gross margin | 82.8% | 97.1% | — | — | — |
| Operating income | -$84.4M | -$89.5M | -$82.2M | -$123.5M | -$69.7M |
| Net income | -$79.6M | -$77.3M | -$73.8M | -$120.7M | -$76.0M |
| Net margin | −574.5% | −478.9% | — | — | — |
| Diluted EPS | $-1.28 | $-1.32 | $-1.85 | $-3.65 | $-8.95 |
| EBITDA | -$79.9M | -$65.5M | -$80.3M | -$122.8M | -$69.1M |
| Operating cash flow | -$63.5M | -$57.7M | -$70.7M | -$89.3M | -$35.3M |
| Free cash flow | -$63.5M | -$57.9M | -$77.4M | -$95.7M | -$35.9M |
| Diluted shares | 62.1M | 58.4M | 39.9M | 33.0M | 8.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $15.4M | $19.5M | $9.7M | $179.3M | $274.7M |
| Short-term investments | $51.4M | $107.5M | $109.6M | $0.00 | — |
| Total debt | $23.0K | $100.0K | $0.00 | $0.00 | $0.00 |
| Total assets | $91.5M | $157.2M | $173.7M | $211.4M | $280.0M |
| Total liabilities | $38.1M | $36.4M | $48.0M | $50.6M | $18.7M |
| Shareholders' equity | $53.4M | $120.8M | $125.7M | $160.8M | $261.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology